🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Super Bowl standout 😎

Herath Poshte! This festival is closely associated with the vibrant culture of our Kashmiri Pandit sisters and brothers. On this auspicious occasion, I wish for harmony, good health and prosperity for everyone. May it also fulfil dreams, create new opportunities and bring

We are thrilled to share that the U.S. FDA has approved our supplemental New Drug Application (sNDA) for AMVUTTRA® (vutrisiran), making it available as a treatment option for a new group of patients. Read the press release: bit.ly/4kHlC1M #RNAi #RNAiTherapeutics

Vutrisiran for transthyrtin amyloid cardiomyopathy is now FDA approved to reduce mortality, CVH, and urgent HF visits Label alnylam.com/sites/default/… #CardioTwitter

A monumental day for the #ATTR #amyloidosis field: #Vutrisiran is now FDA approved for ATTR-CM! The landmark #HELIOS-B trial hit 10/10 prespecified endpoints including improved all-cause mortality. Congratulations to everyone who contributed to the development/approval, and a

And then there were 3! Ronald Witteles Ahmad Masri Martha Grogan MD Mazen Hanna Brett Sperry, MD Kevin Alexander Yevgeniy Brailovsky DO MSc FACC Melissa Lyle Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Justin L. Grodin investors.alnylam.com/press-release?…

1/7 Vutrisiran (AMVUTTRA) is an RNAi therapeutic indicated for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR). A game-changer for a devastating progressive disease. [1]

#Alnylamproud

#LFGM

businesswire.com/news/home/2025…

HELIOS-B: #Vutrisiran reduces all-cause mortality, presented by Marianna Fontana 📍 Significant reduction in all-cause & #CVdeath ☠️ over 42 months vs placebo 📍 Lower rates of #CVevents and #HF hospitalisations 🏥 over 36 months vs placebo #ATTR #cardiacamyloidosis

investors.alnylam.com/press-release?… – Additional 42-Month Data Reinforce Vutrisiran’s Impact on the Risk of All-Cause Mortality and CV Mortality – Substantial Benefit Across a Range of CV Events, Notably Reducing Urgent Heart Failure Visits by 46%

Enjoyed speaking with Michelle Kittleson MD PhD about new analyses of #vutrisiran in #HELIOS-B — presented today at European Society of Cardiology HF meeting and simultaneously published in JACC Journals. jacc.org/digital-conten…

.Wilfried Mullens is joined by Marianna Fontana and Johann Bauersachs to discuss the HELIOS-B trial and how vutrisiran reduces all-cause mortality during #HeartFailure2025 Watch their #HFASnacks 🤗 #HFA_ESC HFAPresident

#alnylamproud

Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B vutrisiran reliably reduced the risk of ACM, CV mortality, CV hospitalizations, HF hospitalizations, and urgent HF visit #HeartFailure2025 jacc.org/doi/10.1016/j.…

📉 Earlier is better: Vutrisiran works across ATTR-CM stages, but the biggest survival gains come in early disease. Time is myocardium. jacc.org/doi/10.1016/j.… #JACC #HELIOSB #ATTRCM #Vutrisiran #Amyloidosis mathew.maurer Ronald Witteles

More than 50% reduction in uacr with combo and about 30% with each component that is empagliflozin and finerenone. Time to consider simultaneous initiation of combination therapy in ckd and t2d as in hfref and stage 2 hypertension.

RIP, Prince of darkness!